Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Expanded Access Protocol for Providing Tabelecleucel to Patients With Epstein-Barr Virus-Associated Viremia or Malignancies for Whom There Are No Appropriate Alternative Therapies

Trial Profile

Expanded Access Protocol for Providing Tabelecleucel to Patients With Epstein-Barr Virus-Associated Viremia or Malignancies for Whom There Are No Appropriate Alternative Therapies

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 15 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tabelecleucel (Primary)
  • Indications Leiomyosarcoma; Lymphoproliferative disorders; Nasopharyngeal cancer; Post-transplant lymphoproliferative disorder; Viraemia
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Sponsors Atara Biotherapeutics
  • Most Recent Events

    • 04 Nov 2021 According to an Atara Biotherapeutics media release, additional data from this trial will be presented at the 63rd American Society of Hematology (ASH) Annual Meeting 2021.
    • 01 Sep 2021 Results(n=26) reporting aggregate OS from three studies (NCT00002663, NCT01498484 and NCT02822495) in patients with EBV+ PTLDafter SOT with CR or PR with tabelecleucel treatment presented at the 20th Congress of the European Society for Organ Transplantation
    • 07 Jun 2021 According to an Atara Biotherapeutics media release, pooled data from 95-024, 11-130 and EAP-201 studies were featured at the oral plenary of 2021 American Transplant Congress (ATC 2021 Virtual Connect).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top